drug · small molecule
osimertinib mesylate
Marketedupdated 6mo agoby $AZN ASTRAZENECA PLC🔗 ChEMBL
Approvedannual revenue · 2024–2024peak $6.6B
community read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for non-small cell lung carcinoma and 1 investigational indication.
indications
investigational
NSCLC
targets
Epidermal growth factor receptor
all catalysts(0)
nothing on the calendar yet
Trials studying osimertinib mesylate
- phase2A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC
- phase1Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer
- phase3A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
- phase2A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
- phase1A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients
- phase2A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
- phase2A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
- phase2A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 16, 2027
91 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (10)
- Nov 26, 2042method-of-use (U-3823)US 12465608
- Nov 26, 2042method-of-use (U-3823)US 12465608
- Jan 2, 2035formulationUS 10183020
- Jan 2, 2035formulationUS 10183020
- Aug 8, 2032compositionUS 8946235
- Aug 8, 2032compositionUS 8946235
- Jul 25, 2032compositionUS 11524951
- Jul 25, 2032compositionUS 11524951
- Jul 25, 2032compositionUS 9732058
- Jul 25, 2032compositionUS 9732058
FDA exclusivities (6)
- Dec 18, 2027ODE-337Orphan Drug (7y)1.1y
- Dec 18, 2027ODE-337Orphan Drug (7y)1.1y
- Sep 25, 2027I-952Indication (3y)312d
- Sep 25, 2027I-952Indication (3y)312d
- Feb 16, 2027I-941Indication (3y)91d
- Feb 16, 2027I-941Indication (3y)91d
News(10)
- AstraZeneca employs $1.5B cost savings to reinvest back into growth“You don't spend one and a half billion dollars without creating jobs,” AstraZeneca CEO Pascal Soriot said as the pharma announced a new cost savings program alongside third quarter earnings.biospace · 17d ago
- #ESMO26: SystImmune/BMS and Hengrui detail data in EGFR-mutant lung cancerMADRID — Several drugmakers with antibody-drug conjugates are jockeying for a spot in EGFR-mutant non-small cell lung cancer patients who progress after AstraZeneca’s Tagrisso. And it seems that th…endpoints · 21d ago
- #ESMO26: AstraZeneca's Tagrisso-Orpathys combo may extend Tagrisso's life in lung cancerMADRID — AstraZeneca said Sunday it might have found a way for patients with mutant non-small cell lung cancer to keep taking Tagrisso even after they have become resistant to the EGFR-targeting ty…endpoints · 22d ago
- Pharma’s $500B patent problem will come in waves — not as a cliffMerck is the most vulnerable to generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.biopharma_dive · 1mo ago
- ArriVent sheds nearly half of value on late-stage lung cancer missArriVent BioPharma’s Phase 3 lung cancer trial was clouded by stronger-than-expected data for patients receiving chemotherapy, prompting analysts to pivot focus to a late-stage test of the tyrosine…biospace · 1mo ago
- Rare EGFR mutation increases lung cancer risk 62 times in never smokersA rare inherited germline mutation was found to increase risk for lung cancer by 25 times, while smoking only increased risk by 4 times.fiercebiotech · 2mo ago
- WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlightThe year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability of results from China-run studies.biopharma_dive · 2mo ago
- Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancerCullinan Therapeutics and Taiho Oncology unveiled phase 3 data showing survival improvements greater than Johnson & Johnson’s Rybrevant in patients with advanced non-small cell lung cancer in the f…fiercebiotech · 2mo ago
- GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer assetGSK is handing over $110 million upfront to Hutchmed in a deal worth up to $1.295 billion to get its hands on a first-in-class oncology candidate.fiercebiotech · 2mo ago
- AstraZeneca scores in lung cancer; Sandoz inks a China dealA combination of AstraZeneca’s Tagrisso and Hutchmed’s Orpathys extended survival for some lung cancer patients. Elsewhere, MapLight floated the idea of partnering on its autism drug.biopharma_dive · 3mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that